• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Social Capital Suvretta Holdings Corp. II filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    6/29/22 4:15:41 PM ET
    $DNAB
    Blank Checks
    Finance
    Get the next $DNAB alert in real time by email
    Form 8-K
    NASDAQ false 0001850271 0001850271 2022-06-29 2022-06-29

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 29, 2022

     

     

    SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. II

    (Exact name of registrant as specified in its charter)

     

     

    Commission file number: 001-40559

     

    Cayman Islands   98-1586137
    (State of incorporation)  

    (I.R.S. Employer

    Identification No.)

     

    2850 W. Horizon Ridge Parkway, Suite 200

    Henderson, NV

      89052
    (Address of principal executive offices)   (Zip Code)

    (650)-521-9007

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol

     

    Name of each exchange

    on which registered

    Class A ordinary shares, $0.0001 par value per share   DNAB   Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 29, 2022, Robert Berman was appointed to the board of directors (the “Board”) of Social Capital Suvretta Holdings Corp. II (the “Company”). Effective June 29, 2022, Dr. Berman was also appointed to the audit committee, the compensation committee and the nominating and corporate governance committee of the Board. The Board has determined that Dr. Berman is an independent director under applicable Securities and Exchange Commission and Nasdaq Capital Market rules.

    In connection with the appointment of Dr. Berman, the Company entered into the following agreements:

     

      •  

    A Letter Agreement, dated June 29, 2022 (the “Letter Agreement”), between the Company and Dr. Berman, pursuant to which Dr. Berman has agreed to: vote any ordinary shares of the Company held by him in favor of the Company’s initial business combination; facilitate the liquidation and winding up of the Company if an initial business combination is not consummated within the time period required by the Company’s amended and restated memorandum and articles of association; and certain transfer restrictions with respect to the Company’s securities.

     

      •  

    An Indemnity Agreement, dated June 29, 2022 (the “Indemnity Agreement”), between the Company and Dr. Berman, providing Dr. Berman contractual indemnification in addition to the indemnification provided for in the Company’s amended and restated memorandum and articles of association.

     

      •  

    A Director Restricted Stock Unit Award Agreement, dated June 29, 2022 (the “Restricted Stock Unit Award Agreement”), between the Company and Dr. Berman, providing for the grant of 30,000 restricted stock units (“RSUs”) to Dr. Berman, which grant is contingent on (i) the Company’s consummation of an initial business combination and (ii) a shareholder approved equity plan. The RSUs will vest upon the consummation of such initial business combination (the “Vesting Date”) and represent 30,000 Class A ordinary shares (or, following a domestication by the Company as a Delaware corporation, shares of common stock) of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the Vesting Date and March 15 of the year following the year in which vesting occurs.

    The foregoing descriptions of the Letter Agreement, the Indemnity Agreement and Restricted Stock Unit Award Agreement do not purport to be complete and are qualified in their entireties by reference to the Letter Agreement, the Indemnity Agreement and Restricted Stock Unit Award Agreement, copies of which are attached hereto as Exhibits 10.1, 10.2 and 10.3, respectively, and are incorporated herein by reference.

    The Company will reimburse Dr. Berman for reasonable out-of-pocket expenses incurred in connection with fulfilling his role as a director. Other than the foregoing, Dr. Berman is not party to any arrangement or understanding with any person pursuant to which he was appointed as a director, nor is he party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.
      

    Description

    10.1    Letter Agreement, dated June 29, 2022, between the Company and Dr. Berman.
    10.2    Indemnity Agreement, dated June 29, 2022, between the Company and Dr. Berman.
    10.3    Director Restricted Stock Unit Award Agreement, dated June 29, 2022, between the Company and Dr. Berman.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. II
    By:  

    /s/ James Ryans

      James Ryans
      Chief Financial Officer

    Dated: June 29, 2022

    Get the next $DNAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAB
    SEC Filings

    View All

    SEC Form 15-12G filed by Social Capital Suvretta Holdings Corp. II

    15-12G - Social Capital Suvretta Holdings Corp. II (0001850271) (Filer)

    7/11/23 12:59:58 PM ET
    $DNAB
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Social Capital Suvretta Holdings Corp. II

    25-NSE - Social Capital Suvretta Holdings Corp. II (0001850271) (Subject)

    6/30/23 5:00:30 PM ET
    $DNAB
    Blank Checks
    Finance

    Social Capital Suvretta Holdings Corp. II filed SEC Form 8-K: Other Events

    8-K - Social Capital Suvretta Holdings Corp. II (0001850271) (Filer)

    5/26/23 4:46:12 PM ET
    $DNAB
    Blank Checks
    Finance

    $DNAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Berman Robert

    3 - Social Capital Suvretta Holdings Corp. II (0001850271) (Issuer)

    7/6/22 4:31:42 PM ET
    $DNAB
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Nolan Sean P.

    3 - Social Capital Suvretta Holdings Corp. II (0001850271) (Issuer)

    9/24/21 4:51:50 PM ET
    $DNAB
    Blank Checks
    Finance

    SEC Form 4 filed by Social Capital Suvretta Holdings Corp. II

    4 - Social Capital Suvretta Holdings Corp. II (0001850271) (Issuer)

    8/16/21 6:28:29 PM ET
    $DNAB
    Blank Checks
    Finance

    $DNAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Social Capital Suvretta Holdings Corp. II (Amendment)

    SC 13G/A - Social Capital Suvretta Holdings Corp. II (0001850271) (Subject)

    2/8/24 1:05:37 PM ET
    $DNAB
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Social Capital Suvretta Holdings Corp. II (Amendment)

    SC 13G/A - Social Capital Suvretta Holdings Corp. II (0001850271) (Subject)

    8/10/23 11:29:30 AM ET
    $DNAB
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Social Capital Suvretta Holdings Corp. II (Amendment)

    SC 13G/A - Social Capital Suvretta Holdings Corp. II (0001850271) (Subject)

    3/10/23 11:08:55 AM ET
    $DNAB
    Blank Checks
    Finance